Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476679 · ClinicalTrials.gov registry record · Phase 1
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
A Phase 1 study, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05476679 is a Phase 1 study that has completed, run by Raziel Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT05476679, a Phase 1 study, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:
Interventions
- DRUG RZL-012
- DRUG RZL-012+Lidacaine injection prior treatment
- DRUG RZL-012+Medrol
- DRUG RZL-012+Celecoxib+Zyrtec
- DRUG RZL-012+facial and neck wrap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-09-25 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05476679
The ClinicalTrials.gov registry entry for NCT05476679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which RZL-012 is the first listed.
NCT05476679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05476679 about?
NCT05476679 is a clinical study titled "Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events". This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:
What is the current status of trial NCT05476679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-09-25. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT05476679?
The interventions under investigation include: RZL-012 (DRUG), RZL-012+Lidacaine injection prior treatment (DRUG), RZL-012+Medrol (DRUG), RZL-012+Celecoxib+Zyrtec (DRUG), RZL-012+facial and neck wrap (DRUG).
Who is sponsoring clinical trial NCT05476679?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.